The results from the focused protein microarray showed that autoantibody to GNAS in level and frequency was significantly higher in HCC patients than that in normal controls; it can distinguish 40.6% of HCC patients from normal controls with an AUC of 0.618 (Figure 2A–C). This evidence concerns the gene GNAS and hepatocellular carcinoma.